Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Spasticity in multiple sclerosis.

Barnes MP, Kent RM, Semlyen JK, McMullen KM.

Neurorehabil Neural Repair. 2003 Mar;17(1):66-70.

PMID:
12645447
2.

Anti-spasticity agents for multiple sclerosis.

Shakespeare DT, Boggild M, Young C.

Cochrane Database Syst Rev. 2003;(4):CD001332. Review.

PMID:
14583932
3.

Anti-spasticity agents for multiple sclerosis.

Shakespeare DT, Boggild M, Young C.

Cochrane Database Syst Rev. 2001;(4):CD001332. Review. Update in: Cochrane Database Syst Rev. 2003;(4):CD001332.

PMID:
11687107
4.

Anti-spasticity agents for multiple sclerosis.

Shakespeare DT, Young CA, Boggild M.

Cochrane Database Syst Rev. 2000;(4):CD001332. Review. Update in: Cochrane Database Syst Rev. 2001;(4):CD001332.

PMID:
11034714
5.

Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up.

Rekand T, Grønning M.

J Rehabil Med. 2011 May;43(6):511-4. doi: 10.2340/16501977-0811.

6.

Drug treatments for spasticity.

Yelnik AP, Simon O, Bensmail D, Chaleat-Valayer E, Decq P, Dehail P, Quentin V, Marque P, Parratte B, Pellas F, Rousseaux M, Trocello JM, Uzzan M, Dumarcet N; Agence française de sécurité sanitaire des produits de santé.

Ann Phys Rehabil Med. 2009 Dec;52(10):746-56. doi: 10.1016/j.rehab.2009.09.005. Epub 2009 Nov 4. No abstract available.

7.

Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial.

Cutter NC, Scott DD, Johnson JC, Whiteneck G.

Arch Phys Med Rehabil. 2000 Feb;81(2):164-9.

PMID:
10668769
8.

Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.

Eyssette M, Rohmer F, Serratrice G, Warter JM, Boisson D.

Curr Med Res Opin. 1988;10(10):699-708.

PMID:
3286128
9.

Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up.

Azouvi P, Mane M, Thiebaut JB, Denys P, Remy-Neris O, Bussel B.

Arch Phys Med Rehabil. 1996 Jan;77(1):35-9.

PMID:
8554471
10.

Quality of life: effect of reduced spasticity from intrathecal baclofen.

Gianino JM, York MM, Paice JA, Shott S.

J Neurosci Nurs. 1998 Feb;30(1):47-54.

PMID:
9604822
11.

Spasticity.

Rush R, Kumbhare D.

CMAJ. 2015 Apr 7;187(6):436. doi: 10.1503/cmaj.140405. Epub 2014 Nov 17. No abstract available.

12.
13.

Transcutaneous electrical nerve stimulation versus baclofen in spasticity: clinical and electrophysiologic comparison.

Aydin G, Tomruk S, Keleş I, Demir SO, Orkun S.

Am J Phys Med Rehabil. 2005 Aug;84(8):584-92.

PMID:
16034227
14.

[Pharmacological treatment of spasticity in multiple sclerosis].

Heinzlef O, Monteil-Roch I.

Rev Neurol (Paris). 2012 Apr;168 Suppl 3:S62-8. doi: 10.1016/S0035-3787(12)70049-8. Review. French.

PMID:
22721367
15.
16.

Botulinum toxin should be first-line treatment for poststroke spasticity.

Sheean G.

J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):359. doi: 10.1136/jnnp.2008.164889. No abstract available.

PMID:
19289475
17.

Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients.

Ben Smail D, Peskine A, Roche N, Mailhan L, Thiébaut I, Bussel B.

Mult Scler. 2006 Feb;12(1):101-3.

PMID:
16459726
18.

Treatments for spasticity and pain in multiple sclerosis: a systematic review.

Beard S, Hunn A, Wight J.

Health Technol Assess. 2003;7(40):iii, ix-x, 1-111. Review.

19.

BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.

Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, Barnes M, Ford G, Graham L; BoTULS investigators.

Health Technol Assess. 2010 May;14(26):1-113, iii-iv. doi: 10.3310/hta14260.

20.

Intrathecal baclofen for muscle spasticity and pain--two case reports.

Al Khudhairi D, Rababa A, Saddiqui MN.

Middle East J Anaesthesiol. 2006 Jun;18(5):971-6. No abstract available.

PMID:
17094537

Supplemental Content

Support Center